Trials / Withdrawn
WithdrawnNCT03509298
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic Cancer
Phase II Randomized Comparison Clinical Trial of Target Activated CIK for Advanced Pancreatic Cancer
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Fuda Cancer Hospital, Guangzhou · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase II Randomized comparison clinical trial of activated CIK armed with anti-CD3-MUC1 bispecific antibody for advanced pancreatic cancer. And the aim of this research is to study the clinical efficacy and safety of activated CIK armed with anti-CD3-MUC1 bispecific antibody for pancreatic cancer.
Detailed description
Primary pancreatic carcinoma is one of the most common malignancies in China, immunotherapy is considered to be one of the most promising means of human against cancer. This is a phase II clinical trial of single- center, The investigators plan to recruit for 90 patients with advanced pancreatic cancer,and all patients are divided into three groups.one group will receive cryotherapy, one group will receive conventional therapy，and the rest one will receive mixed liquor of activated CIK and anti-CD3-MUC1 bispecific antibody together with cryotherapy. The result of this study was statistic and analysed with the record of Response Evaluation Criteria In Solid Tumors(RECIST1.1) evaluation standard.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Pancreatic Cancer | CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1 |
| PROCEDURE | cryotherapy | the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion. |
Timeline
- Start date
- 2018-04-12
- Primary completion
- 2020-05-20
- Completion
- 2020-07-12
- First posted
- 2018-04-26
- Last updated
- 2020-10-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03509298. Inclusion in this directory is not an endorsement.